Gene Therapy Approaches for Treating HPV-Induced Damage in Human Tissues and Cells
Abstract
Human papillomavirus (HPV) is a leading cause of cervical and other anogenital and oropharyngeal cancers, with high-risk HPV types such as HPV-16 and HPV-18 playing a major role in oncogenesis. The viral oncoproteins E6 and E7 interfere with tumor suppressor proteins p53 and retinoblastoma (pRb), leading to uncontrolled cell proliferation, genetic instability, and resistance to apoptosis. While HPV vaccines have significantly reduced infection rates, they do not eliminate pre-existing infections or treat HPV-associated malignancies. This has driven interest in gene therapy as a potential treatment option for HPV-induced cellular damage. Gene therapy approaches, particularly CRISPR-Cas9, have demonstrated efficacy in selectively targeting and disrupting HPV oncogenes, leading to tumor regression. Other gene-editing techniques, such as zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), also show promise in HPV gene disruption. Efficient delivery systems, including viral and non-viral vectors such as nanoparticles, liposomes, and adeno-associated viruses (AAVs), are being optimized to enhance therapeutic outcomes. However, challenges remain, particularly concerning off-target effects, delivery efficiency, and potential immunogenic responses. This review explores the mechanisms of HPV-induced carcinogenesis, the role of gene therapy in targeting viral oncogenes, and advancements in gene-editing technologies. Future directions include integrating gene therapy with immunotherapy, developing personalized treatment strategies, and improving delivery mechanisms to enhance specificity and safety. While gene therapy holds significant promise for eradicating HPV-driven malignancies, further research is needed to refine these approaches for clinical application.
Keywords:
Oncology, Cancer biology, Molecular biology, Biochemistry, Biotechnology, GenomicsFull Text:
PDFReferences
Castellsagué X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecologic Oncology, (2008); 110(3): S4–7.
Garland SM. Human papillomavirus update with a particular focus on cervical disease. Pathology, (2002); 34(3): 213–24.
Colpani V, Soares Falcetta F, Bacelo Bidinotto A, Kops NL, Falavigna M, Serpa Hammes L, et al. Prevalence of human papillomavirus (HPV) in Brazil: A systematic review and meta-analysis. PLOS ONE, (2020); 15(2): e0229154.
Boulet G, Horvath C, Broeck DV, Sahebali S, Bogers J. Human papillomavirus: E6 and E7 oncogenes. International Journal of Biochemistry and Cell Biology, (2007); 39(11): 2006–11.
Yeo-Teh NSL, Ito Y, Jha S. High-Risk Human Papillomaviral Oncogenes E6 and E7 Target Key Cellular Pathways to Achieve Oncogenesis. International Journal of Molecular Sciences, (2018); 19(6): 1706.
Janiszewska J, Kostrzewska-Poczekaj M, Wierzbicka M, Brenner JC, Giefing M. HPV-driven oncogenesis—much more than the E6 and E7 oncoproteins. Journal of Applied Genetics, (2025); 66(1): 63-71.
Zhen S, Li X. Oncogenic Human Papillomavirus: Application of CRISPR/Cas9 Therapeutic Strategies for Cervical Cancer. Cell Physiology and Biochemistry, (2017); 44(6): 2455–66.
Inturi R, Jemth P. CRISPR/Cas9-based inactivation of human papillomavirus oncogenes E6 or E7 induces senescence in cervical cancer cells. Virology, (2021); 562: 92–102.
Scarth JA, Patterson MR, Morgan EL, Macdonald A. The human papillomavirus oncoproteins: a review of the host pathways targeted on the road to transformation. Journal of General Virology, (2021); 102(3): 001540.
Okunade KS. Human papillomavirus and cervical cancer. Journal of Obstetrics and Gynaecology, (2020); 40(5): 602–8.
Yoshiba T, Saga Y, Urabe M, Uchibor R, Matsubara S, Fujiwara H, et al. CRISPR/Cas9-mediated cervical cancer treatment targeting human papillomavirus E6. Oncology Letters, (2018): 17(2): 2197-2206.
Smalley Rumfield C, Roller N, Pellom ST, Schlom J, Jochems C. Therapeutic Vaccines for HPV-Associated Malignancies. ImmunoTargets and Therapy, (2020); 9: 167–200.
Cheng MA, Farmer E, Huang C, Lin J, Hung CF, Wu TC. Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases. Human Gene Therapy, (2018); 29(9): 971–96.
Estêvão D, Costa NR, Gil Da Costa RM, Medeiros R. Hallmarks of HPV carcinogenesis: The role of E6, E7 and E5 oncoproteins in cellular malignancy. Biochimica et Biophysica Acta – Gene Regulatory Mechanisms, (2019); 1862(2): 153–62.
Kennedy EM, Kornepati AVR, Goldstein M, Bogerd HP, Poling BC, Whisnant AW, et al. Inactivation of the Human Papillomavirus E6 or E7 Gene in Cervical Carcinoma Cells by Using a Bacterial CRISPR/Cas RNA-Guided Endonuclease. Journal of Virology, (2014); 88(20): 11965–72.
Gupta S, Kumar P, Das BC. HPV: Molecular pathways and targets. Current Problems in Cancer, (2018); 42(2): 161–74.
Doran SL, Stevanović S, Adhikary S, Gartner JJ, Jia L, Kwong MLM, et al. T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study. Journal of Clinical Oncology, (2019); 37(30): 2759–68.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, (2018); 68(6): 394–424.
Arbyn M, Castellsagué X, De Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Annals of Oncology, (2011); 22(12): 2675–86.
Almeida AM, Queiroz JA, Sousa F, Sousa Â. Cervical cancer and HPV infection: ongoing therapeutic research to counteract the action of E6 and E7 oncoproteins. Drug Discovery Today, (2019); 24(10): 2044–57.
Gao C, Wu P, Yu L, Liu L, Liu H, Tan X, et al. The application of CRISPR/Cas9 system in cervical carcinogenesis. Cancer Gene Therapy, (2022); 29(5): 466–74.
Bello J, Nieva L, Paredes A, Gonzalez A, Zavaleta L, Lizano M. Regulation of the Wnt/β-Catenin Signaling Pathway by Human Papillomavirus E6 and E7 Oncoproteins. Viruses, (2015); 7(8): 4734–55.
Noroozi Z, Shamsara M, Valipour E, Esfandyari S, Ehghaghi A, Monfaredan A, et al. Antiproliferative effects of AAV-delivered CRISPR/Cas9-based degradation of the HPV18-E6 gene in HeLa cells. Scientific Reports, (2022); 12(1): 2224.
Zhen S, Hua L, Takahashi Y, Narita S, Liu YH, Li Y. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. Biochemical and Biophysical Research Communications, (2014); 450(4): 1422–6.
Medda A, Duca D, Chiocca S. Human Papillomavirus and Cellular Pathways: Hits and Targets. Pathogens, (2021); 10(3): 262.
Wei Y, Zhao Z, Ma X. Description of CRISPR-Cas9 development and its prospects in human papillomavirus-driven cancer treatment. Frontiers in Immunology, (2022); 13: 1037124.
Mittal S, Banks L. Molecular mechanisms underlying human papillomavirus E6 and E7 oncoprotein-induced cell transformation. Mutation Research – Reviews in Mutation Research, (2017); 772: 23–35.
Arroyo Mühr LS, Lagheden C, Lei J, Eklund C, Nordqvist Kleppe S, Sparén P, et al. Deep sequencing detects human papillomavirus (HPV) in cervical cancers negative for HPV by PCR. British Journal of Cancer, (2020); 123(12): 1790–5.
Folliero V, Dell’Annunziata F, Chianese A, Morone M, Mensitieri F, Di Spirito F, et al. Epigenetic and Genetic Keys to Fight HPV-Related Cancers. Cancers, (2023); 15(23): 5583.
Taha EA, Lee J, Hotta A. Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges. Journal of Controlled Release, (2022); 342: 345–61.
Fu Y, He X, Gao XD, Li F, Ge S, Yang Z, et al. Prime editing: current advances and therapeutic opportunities in human diseases. Science Bulletin, (2023); 68(24): 3278–91.
Rasul MF, Hussen BM, Salihi A, Ismael BS, Jalal PJ, Zanichelli A, et al. Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy. Molecular Cancer, (2022); 21(1): 64.
Lin M, Qi X. Advances and Challenges of Stimuli-Responsive Nucleic Acids Delivery System in Gene Therapy. Pharmaceutics, (2023); 15(5): 1450.
Chen C, Zhong W, Du S, Li Y, Zeng Y, Liu K, et al. Intelligent nanotherapeutic strategies for the delivery of CRISPR system. Acta Pharmaceutica Sinica B, (2023); 13(6): 2510–43.
Peng R, Lin G, Li J. Potential pitfalls of CRISPR/Cas9-mediated genome editing. FEBS Journal, (2016); 283(7): 1218–31.
Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science, (2014); 346(6213): 1258096.
Gupta D, Bhattacharjee O, Mandal D, Sen MK, Dey D, Dasgupta A, et al. CRISPR-Cas9 system: A new-fangled dawn in gene editing. Life Sciences, (2019); 232: 116636.
Jubair L, Fallaha S, McMillan NAJ. Systemic Delivery of CRISPR/Cas9 Targeting HPV Oncogenes Is Effective at Eliminating Established Tumors. Molecular Therapy, (2019); 27(12): 2091–9.
Wang X, Huang X, Zhang Y. Involvement of Human Papillomaviruses in Cervical Cancer. Frontiers in Microbiology, (2018); 9: 2896.
Yugawa T, Kiyono T. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Reviews in Medical Virology, (2009); 19(2): 97–113.
Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: Roles of E6 and E7 proteins. Cancer Science, (2007); 98(10): 1505–11.
Pal A, Kundu R. Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. Frontiers in Microbiology, (2020); 10: 3116.
Áyen Á, Jiménez Martínez Y, Boulaiz H. Targeted Gene Delivery Therapies for Cervical Cancer. Cancers, (2020); 12(5): 1301.
Roma-Rodrigues C, Rivas-García L, Baptista PV, Fernandes AR. Gene Therapy in Cancer Treatment: Why Go Nano? Pharmaceutics, (2020); 12(3): 233.
Cring MR, Sheffield VC. Gene therapy and gene correction: targets, progress, and challenges for treating human diseases. Gene Therapy, (2022); 29(1–2): 3–12.
Gardlík R, Pálffy R, Hodosy J, Lukács J, Turna J, Celec P. Vectors and delivery systems in gene therapy. Medical Science Monitor, (2005); 11(4): RA110-121.
Ramamoorth M, Narvekar A. Non viral vectors in gene therapy- an overview. Journal of Clinical and Diagnostic Research, (2015); 9(1): GE01-06.
Chen YH, Keiser MS, Davidson BL. Viral Vectors for Gene Transfer. Current Protocols in Mouse Biology, (2018); 8(4): e58.
Chitsike L, Duerksen-Hughes PJ. PPI Modulators of E6 as Potential Targeted Therapeutics for Cervical Cancer: Progress and Challenges in Targeting E6. Molecules, (2021); 26(10): 3004.
Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell, (2011); 144(5): 646–74.
Felsani A, Mileo AM, Paggi MG. Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins. Oncogene, (2006); 25(38): 5277–85.
Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nature Reviews Cancer, (2008); 8(9): 671–82.
McMellen A, Woodruff ER, Corr BR, Bitler BG, Moroney MR. Wnt Signaling in Gynecologic Malignancies. International Journal of Molecular Sciences, (2020); 21(12): 4272.
Shiri Aghbash P, Hemmat N, Baradaran B, Mokhtarzadeh A, Poortahmasebi V, Ahangar Oskuee M, et al. The effect of Wnt/β-catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer. Oncology Research, (2022); 30(3): 99–116.
Porter VL, Marra MA. The Drivers, Mechanisms, and Consequences of Genome Instability in HPV-Driven Cancers. Cancers, (2022); 14(19): 4623.
Korzeniewski N, Spardy N, Duensing A, Duensing S. Genomic instability and cancer: Lessons learned from human papillomaviruses. Cancer Letters, (2011); 305(2): 113–22.
Litwin T, Clarke M, Dean M, Wentzensen N. Somatic Host Cell Alterations in HPV Carcinogenesis. Viruses, (2017); 9(8): 206.
Senapati R, Senapati NN, Dwibedi B. Molecular mechanisms of HPV mediated neoplastic progression. Infectious Agents and Cancer, (2016); 11(1): 59.
Hu Z, Yu L, Zhu D, Ding W, Wang X, Zhang C, et al. Disruption of HPV16-E7 by CRISPR/Cas System Induces Apoptosis and Growth Inhibition in HPV16 Positive Human Cervical Cancer Cells. BioMed Research International, (2014); 2014: 1–9.
Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nature Biotechnology, (2014); 32(4): 347–55.
Sharma G, Sharma AR, Bhattacharya M, Lee SS, Chakraborty C. CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases. Molecular Therapy, (2021); 29(2): 571–86.
LaFountaine JS, Fathe K, Smyth HDC. Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9. International Journal of Pharmaceutics, (2015); 494(1): 180–94.
Song X, Liu C, Wang N, Huang H, He S, Gong C, et al. Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy. Advanced Drug Delivery Reviews, (2021); 168: 158–80.
Jubair L, Lam AK, Fallaha S, McMillan NAJ. CRISPR/Cas9-loaded stealth liposomes effectively cleared established HPV16-driven tumours in syngeneic mice. PLOS ONE, (2021); 16(1): e0223288.
Cui Z, Liu H, Zhang H, Huang Z, Tian R, Li L, et al. The comparison of ZFNs, TALENs, and SpCas9 by GUIDE-seq in HPV-targeted gene therapy. Molecular Therapy – Nucleic Acids, (2021); 26: 1466–78.
Kazemian P, Yu SY, Thomson SB, Birkenshaw A, Leavitt BR, Ross CJD. Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components. Molecular Pharmaceutics, (2022); 19(6): 1669–86.
Hu Z, Ma D. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Medicine, (2018); 7(10): 5217–36.
Gaj T, Gersbach CA, Barbas CF. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends in Biotechnology, (2013); 31(7): 397–405.
Nsairat H, Alshaer W, Odeh F, Esawi E, Khater D, Bawab AA, et al. Recent advances in using liposomes for delivery of nucleic acid-based therapeutics. OpenNano, (2023); 11: 100132.
Rapti K, Grimm D. Adeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog. Frontiers in Immunology, (2021); 12: 753467.
Dhungel BP, Winburn I, Pereira C da F, Huang K, Chhabra A, Rasko JEJ. Understanding AAV vector immunogenicity: from particle to patient. Theranostics, (2024); 14(3): 1260–88.
Rodrigues MC, Morais JAV, Ganassin R, Oliveira GRT, Costa FC, Morais AAC, et al. An Overview on Immunogenic Cell Death in Cancer Biology and Therapy. Pharmaceutics, (2022); 14(8): 1564.
Asadzadeh Z, Safarzadeh E, Safaei S, Baradaran A, Mohammadi A, Hajiasgharzadeh K, et al. Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death. Cancers, (2020); 12(4): 1047.
Guo C, Ma X, Gao F, Guo Y. Off-target effects in CRISPR/Cas9 gene editing. Frontiers in Bioengineering and Biotechnology, (2023); 11: 1143157.
Chira S, Nutu A, Isacescu E, Bica C, Pop L, Ciocan C, et al. Genome Editing Approaches with CRISPR/Cas9 for Cancer Treatment: Critical Appraisal of Preclinical and Clinical Utility, Challenges, and Future Research. Cells, (2022); 11(18): 2781.
Mehta A, Merkel OM. Immunogenicity of Cas9 Protein. Journal of Pharmaceutical Sciences, (2020); 109(1): 62–7.
Sen D, Sarkar S, Mukhopadhyay P. Prime Editing: An Emerging Tool in Cancer Treatment. Molecular Biotechnology, (2023); 65(4): 509–20.
Scholefield J, Harrison PT. Prime editing – an update on the field. Gene Therapy, (2021); 28(7–8): 396–401.
Jung H, Rajasekaran N, Ju W, Shin Y. Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer. Journal of Clinical Medicine, (2015); 4(5): 1126–55.
Polten R, Kutle I, Hachenberg J, Klapdor R, Morgan M, Schambach A. Towards Novel Gene and Cell Therapy Approaches for Cervical Cancer. Cancers, (2022); 15(1): 263.
DOI: https://doi.org/10.62940/als.v13i1.3854
Refbacks
- There are currently no refbacks.